A Dutch study involving more than 1100 men found that the antioxidant supplement Impryl did not improve fertility. The trial, ...

Many trials that measure the efficacy and safety of antidepressants for MDD exclude one third of real-world patients with the ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Sepsis remains one of the leading causes of mortality in hospitalized patients worldwide, and innovative therapeutic ...

A New York Times health reporter explains what makes a good study, and how she knows which papers merit an article.

Trials should assess overall survival to evaluate potential harm, with crossover limited to avoid confounding treatment ...

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ( ...

Impostor participants threaten the integrity of health research, and by extension, the policies and clinical decisions built ...

While adapted CBT is not a cure, it offers a crucial framework for managing the secondary issues (such as anxiety and social ...

"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

Sanofi is conducting a Phase 3 clinical trial titled A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult ...

Calcium supplements do not appear to raise dementia risk. Long-term data support their safety for older women. New findings from (ECU), Curtin University, and the University of Western Australia show ...